SCHEMBL1920365

SCHEMBL1920365

O=[C]c1cccc2ccc3ccccc3c12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 7/20 0.48
ALDH1A1 P00352 7/20 0.48
CYP1A2 P05177 6/20 0.48
HPGD P15428 5/20 0.48
THRB P10828 1/20 0.48
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
TSHR P16473 4/20 0.44
TDP1 Q9NUW8 3/20 0.44
CYP2A6 P11509 3/20 0.44
CYP3A4 P08684 4/20 0.42
MAOA P21397 2/20 0.42
ABCB11 O95342 1/20 0.42
NR3C1 P04150 1/20 0.42
ADRA2A P08913 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
ALOX15 P16050 1/20 0.42
ADRA2C P18825 1/20 0.42
DRD1 P21728 1/20 0.42
SLC6A4 P31645 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9004 0.82 CA1 (0.52) HSD17B10ALDH1A1CYP1A2HPGDTHRB
SCHEMBL6443578 0.82 ALDH1A1 (0.45) HSD17B10ALDH1A1CYP1A2HPGDTHRB
SCHEMBL27950969 0.79 CA1 (0.60) HSD17B10ALDH1A1CYP1A2HPGDTHRB
SCHEMBL194524 0.79 HPRT1 (0.58) HSD17B10ALDH1A1CYP1A2HPGDTHRB
SCHEMBL6129153 0.79 HSD17B10 (0.48) HSD17B10ALDH1A1CYP1A2HPGDTHRB
SCHEMBL19409989 0.78 ALDH1A1 (0.44) HSD17B10ALDH1A1CYP1A2HPGDTHRB
SCHEMBL3745502 0.78 ALDH1A1 (0.52) HSD17B10ALDH1A1CYP1A2HPGDTHRB
SCHEMBL5970913 0.75 CA1 (0.46) HSD17B10ALDH1A1CYP1A2HPGDCA1
SCHEMBL8880857 0.75 ALDH1A1 (0.43) HSD17B10ALDH1A1CYP1A2HPGDTHRB
SCHEMBL3629439 0.74 KDM4E (0.52) HSD17B10ALDH1A1CYP1A2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116813979-A Nucleating agent, synthetic resin composition containing same, and molded article thereof 株式会社ADEKA 2023-09-29 CN disclosed
CN-112839988-B Nucleating agent, synthetic resin composition containing same, and molded article thereof 株式会社ADEKA 2023-06-06 CN disclosed
US-20210395209-A1 NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF ADEKA CORPORATION (JP) 2021-12-23 US disclosed
EP-3858909-A1 NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF ADEKA CORPORATION (JP) 2021-08-04 EP disclosed
CN-112839988-A Nucleating agent, synthetic resin composition containing same, and molded article thereof 株式会社ADEKA 2021-05-25 CN disclosed
US-8394974-B2 Process for producing optically active chromene oxide compound NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2013-03-12 US disclosed
EP-1718629-B1 Benzopyran compounds useful for the treatment of arrhytmia NISSAN CHEMICAL IND LTD (JP) 2012-12-26 EP disclosed
US-7964623-B2 Tricyclic benzopyrane compound NISSAN CHEMICAL INDUSTRIES LTD. (JP) 2011-06-21 US disclosed
EP-1590491-B1 ADDUCTS BASED ON CYCLIC COMPOUNDS AND THE USE THEREOF AS TANNING AGENTS AND CURING AGENTS BASF SE (DE) 2011-06-01 EP disclosed
US-7851503-B2 Thrombopoetin receptor activator and process for producing the same NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2010-12-14 US disclosed
EP-1732929-A1 TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS Nissan Chemical Industries, Ltd. (JP) 2006-12-20 EP disclosed
US-20060101583-A1 Adducts based on cyclic compounds and the use thereof as tanning agents and curing agents BASF AKTIENGESELLSCHAFT (DE) 2006-05-18 US disclosed
US-20060053564-A1 Tanning agents and preservatives BASF AKTIENGESELLSCHAFT (DE) 2006-03-16 US disclosed
US-20050282730-A1 Thrombopoetin receptor activator and process for producing the same NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2005-12-22 US disclosed
EP-1590492-A1 TANNING AGENTS AND PRESERVATIVES BASF AKTIENGESELLSCHAFT (DE) 2005-11-02 EP disclosed
EP-1590491-A1 ADDUCTS BASED ON CYCLIC COMPOUNDS AND THE USE THEREOF AS TANNING AGENTS AND CURING AGENTS BASF Aktiengesellschaft (DE) 2005-11-02 EP disclosed
WO-2005090357-A1 TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2005-09-29 WO disclosed
EP-1552828-A1 THROMBOPOETIN RECEPTOR ACTIVATOR AND PROCESS FOR PRODUCING THE SAME Nissan Chemical Industries, Ltd. (JP) 2005-07-13 EP disclosed
WO-2004067781-A1 ADDUCTS BASED ON CYCLIC COMPOUNDS AND THE USE THEREOF AS TANNING AGENTS AND CURING AGENTS BASF AKTIENGESELLSCHAFT (DE) 2004-08-12 WO disclosed
WO-2004067782-A1 TANNING AGENTS AND PRESERVATIVES BASF AKTIENGESELLSCHAFT (DE) 2004-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210395209-A1 NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF NOC2L, RIF1, NAP1L1 HSD17B10 3823/4885ALDH1A1 2699/4885CYP1A2 3026/4885
US-20050282730-A1 Thrombopoetin receptor activator and process for producing the same PDGFRA, PTAFR, TBXA2R HSD17B10 1809/4885ALDH1A1 2034/4885CYP1A2 1790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.